FY2024 Earnings Estimate for SLDB Issued By Leerink Partnrs

Solid Biosciences Inc. (NASDAQ:SLDB) – Investment analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of Solid Biosciences in a note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($2.86) per share for the year, down from their previous estimate of ($2.61). The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.75) per share. Leerink Partnrs also issued estimates for Solid Biosciences’ Q4 2024 earnings at ($0.81) EPS, Q1 2025 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.19) EPS and FY2026 earnings at ($3.09) EPS.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.12).

A number of other research analysts also recently commented on SLDB. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Solid Biosciences in a research report on Thursday, November 7th. Barclays lowered their price target on shares of Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. William Blair upgraded Solid Biosciences to a “strong-buy” rating in a report on Friday, August 30th. JPMorgan Chase & Co. reduced their price objective on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a research report on Tuesday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a research report on Monday. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $15.14.

Solid Biosciences Price Performance

NASDAQ:SLDB opened at $5.51 on Monday. The stock’s 50-day moving average is $6.73 and its two-hundred day moving average is $7.70. The stock has a market cap of $220.18 million, a PE ratio of -1.81 and a beta of 1.92. Solid Biosciences has a fifty-two week low of $2.00 and a fifty-two week high of $15.05.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Point72 DIFC Ltd acquired a new position in Solid Biosciences during the second quarter valued at approximately $58,000. Ground Swell Capital LLC bought a new stake in shares of Solid Biosciences during the 2nd quarter worth $76,000. Algert Global LLC bought a new stake in shares of Solid Biosciences during the 2nd quarter worth $82,000. Susquehanna Fundamental Investments LLC acquired a new position in Solid Biosciences in the 2nd quarter valued at $92,000. Finally, Valence8 US LP bought a new position in Solid Biosciences in the 3rd quarter worth $110,000. 81.46% of the stock is owned by institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.